UNITEDHEALTH GROUP INC Q3 FY2024 earnings call

• Delivering on growth pillars, serving more consumers, fulfilling prescriptions, and caring for people in value-based arrangements.
• Launched a national gold card program to reduce prior authorizations. Used AI in summarizing patient histories, reviewing documentation, consumer interactions, and software development.
• Progress in value-based care with OptumHealth models showing better cancer screenings, diabetes/hypertension control, and reduced ER visits/readmissions. Emergency room discharge program in eight markets avoids inpatient stays.
• Strong Q3 results with revenues of $101 billion, up over 9% year-over-year, and strong cash flows and shareholder returns.

OptumHealth revenues grew by over $2 billion, approaching $26 billion, driven by increased care services and patients served, especially in home and complex needs. OptumRx revenues grew by over $5 billion to more than $34 billion, boosted by pharmacy care offerings and new customers. OptumInsight revenues were stable, approaching $5 billion with a nearly $33 billion revenue backlog increasing by over $1 billion. UnitedHealthcare's domestic commercial business added over 2.4 million people, Medicare Advantage plans balanced benefit stability with CMS cuts, and Medicaid had strong new customer expansion and retention.

• Full year 2024 earnings outlook remains within the range first offered in Nov 2023.
• For 2025, anticipate a more conservative outlook due to factors like CMS Medicare rate cuts, Medicaid rate mismatches, and care activity. Upper end of likely range for 2025 is around $30 per share. Focus on investing in growth pillars despite external pressures, modernizing with AI, and maintaining discipline in operating performance.

• CMS Medicare rate cuts and impact on member mix.
• State-driven Medicaid member redeterminations and timing mismatches in rates.
• Certain care patterns and health care cyber-attacks.
• Hospital coding intensity upshift and rapid acceleration in specialty drug prescriptions.

Q: Lisa Gill asked about 2025 impacts and OptumRx specialty.

A: Andrew Witty, John Rex, Brian Thompson, Patrick Conway responded discussing factors like IRA impact on specialty drugs, pricing for 2025, and OptumRx's growth in specialty with new products.

Q: A.J. Rice asked about sizing headwinds/tailwinds to 13%-16% growth.

A: Andrew Witty responded about external pressures, investing in long-term growth pillars, and responsible planning for 2025.

Q: Stephen Baxter asked about MLR factors and coding.

A: John Rex and Brian Thompson discussed MLR factors, upcoding issues, and efforts to address inpatient vs outpatient stays.

Q: Josh Raskin asked about Medicare Advantage strategy.

A: Andrew Witty and Tim Noel spoke about MA's importance, diversification of business, and focus on consumer stability and value-based care.

Q: Justin Lake asked about Medicaid and MA margins.

A: Brian Thompson discussed Medicaid redeterminations, Duals business, and MA's outlook on margins.

Q: Scott Fidel asked about commercial business and exchange products.

A: Brian Thompson and Daniel Kueter talked about commercial business trends, pharmacy and hospital costs, and pricing for 2025.

Q: Lance Wilkes asked about OptumHealth.

A: John Rex, Amar Desai, Heather Cianfrocco discussed OptumHealth's performance, value-based care adoption, and services across Optum.

Q: Andrew Mok asked about SG&A permanency.

A: Andrew Witty discussed disciplined cost management and focus on cost reduction and MedEx management.

Q: Erin Wright asked about capital deployment.

A: Andrew Witty and John Rex spoke about capital deployment around growth pillars, value-based care, and consumerization.